Radioiodine in the treatment of thyroid cancer.
This article presents an overview of the use of radioactive iodine (131-I) in the treatment of patients who have well differentiated thyroid cancer. We review definitions; staging; the two-principal methods for selection of a dosage of 131-I for ablation and treatment; the objectives of ablation and treatment; the indications for ablation and treatment; the recommendations for the use of 131-I for ablation and treatment contained in the Guidelines of the American Thyroid Association, the European Consensus, the Society of Nuclear Medicine, and the European Association of Nuclear Medicine; the dosage recommendations and selection of dosage for 131-I by the these organizations; and the Washington Hospital Center approach.
Van Nostrand
Douglas
D
Division of Nuclear Medicine, Washington Hospital Center, and Georgetown University Medical Center, Washington, DC 20010, USA. douglas.van.nostrand@medstar.net
Wartofsky
Leonard
L
D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D009367:Neoplasm Staging; D011829:Radiation Dosage; D013964:Thyroid Neoplasms / Q000473:pathology / Q000532:radiotherapy*
D007457:Iodine Radioisotopes